FKBP5 and glioma: Future in vivo studies with syngeneic mouse models are now needed to validate the efficacy of selective FKBP51 inhibitors in modulating tumour PD-L1 expression and, most importantly, to verify whether these small molecules are able to positively affect tumour microenvironment and ameliorate immune defences against glioma.